Flu Ease
Cairina Moschata Heart/liver Autolysate
Wfm Private Label, Lp
Human Otc Drug
NDC 42681-9281Flu Ease also known as Cairina Moschata Heart/liver Autolysate is a human otc drug labeled by 'Wfm Private Label, Lp'. National Drug Code (NDC) number for Flu Ease is 42681-9281. This drug is available in dosage form of Pellet. The names of the active, medicinal ingredients in Flu Ease drug includes Cairina Moschata Heart/liver Autolysate - 200 [hp_C]/1 . The currest status of Flu Ease drug is Active.
Drug Information:
| Drug NDC: | 42681-9281 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Flu Ease |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Cairina Moschata Heart/liver Autolysate |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Wfm Private Label, Lp |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Pellet |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE - 200 [hp_C]/1
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | ORAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 01 Jan, 2015 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 06 May, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | WFM Private Label, LP
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | RN2HC612GY
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 42681-9281-1 | 18 TUBE in 1 CARTON (42681-9281-1) / 200 PELLET in 1 TUBE | 01 Jan, 2015 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose anas barbariae ....... to reduce the duration and severity of flu-like symptoms.*
Product Elements:
Flu ease cairina moschata heart/liver autolysate sucrose lactose cairina moschata heart/liver autolysate cairina moschata heart/liver autolysate flu ease cairina moschata heart/liver autolysate sucrose lactose cairina moschata heart/liver autolysate cairina moschata heart/liver autolysate
Indications and Usage:
Uses temporarily relieves flu-like symptoms such as: ⢠body aches ⢠headache ⢠fever ⢠chills ⢠fatigue
Warnings:
Ask a doctor before use in children under 2 years of age stop use and ask a doctor if symptoms persist for more than 3 days or worsen. if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. in case of accidental overdose, get medical help or contact a poison control center right away.
Dosage and Administration:
Directions adults and children 2 years and older: at the onset of symptoms, dissolve entire contents of 1 tube in the mouth every 6 hours, up to 3 times a day. children under 2 years: ask a doctor.
Stop Use:
Stop use and ask a doctor if symptoms persist for more than 3 days or worsen.
Package Label Principal Display Panel:
Principle display panel drug facts / tube 6 dose package 18 dose package label drug facts / tube 6 dose package 18 dose package
Further Questions:
Questions, comments? 1-844-wfm-talk (1-844-936-8255)